MYONYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
MYOMO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1.25+0.05 (+4.17%)
Close on Oct 19, 2026
- Market cap
- $53.37M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
30.8%
12M of 40M shares
Institutional holders
80
24 new, 22 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
13 buys · 7 sales
Net bought $231.77K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rosalind Master Fund L.P. | 7,554,046 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Rosalind Advisors, Inc. | 7,401,144 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Salamon Steven A J | 7,359,046 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| Aharon Gil | 7,279,046 | 9.90% | 13G (passive) amendment | Mar 31, 2025 |
| Norbert Gottesman | 2,825,344 | 9.81% | 13G (passive) amendment | Dec 31, 2023 |
| Horton Capital Partners Fund, LP | 2,309,775 | 6.00% | 13D (active) amendment | May 9, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MYO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3,637,886 | 9.18% | $3.78M | −209,386 | 1.41% |
| Vanguard Capital Management LLC | 1,636,570 | 4.13% | $1.70M | +492,246 | 0.00% |
| Aqr Capital Management LLC | 928,268 | 2.34% | $965.40K | +609,317 | 0.00% |
| Jefferies Financial Group Inc. | 704,275 | 1.78% | $732.45K | – | 0.00% |
| Jane Street Group, LLC | 596,352 | 1.51% | $620.21K | New | 0.00% |
| Clearstead Advisors, LLC | 425,609 | 1.07% | $442.64K | +9 | 0.00% |
| UBS Group AG | 413,679 | 1.04% | $430.23K | +101,958 | 0.00% |
| Geode Capital Management, LLC | 344,417 | 0.87% | $358.31K | −514,382 | 0.00% |
| LPL Financial LLC | 308,000 | 0.78% | $320.32K | +2,000 | 0.00% |
| Palumbo Wealth Management LLC | 299,776 | 0.76% | $311.77K | New | 0.07% |
| Gsa Capital Partners Llp | 271,876 | 0.69% | $283 | +50,400 | 0.02% |
| Millennium Management LLC | 271,294 | 0.68% | $282.15K | New | 0.00% |
| BlackRock, Inc. | 223,217 | 0.56% | $232.15K | −1,465,173 | 0.00% |
| Vanguard Fiduciary Trust Co | 207,677 | 0.52% | $215.98K | −29,575 | 0.00% |
| Bnp Paribas Arbitrage, Snc | 139,194 | 0.35% | $144.76K | +131,048 | 0.00% |
| Ieq Capital, LLC | 127,749 | 0.32% | $132.86K | +93,910 | 0.00% |
| Susquehanna International Group, Llp | 120,791 | 0.30% | $125.62K | +82,402 | 0.00% |
| XTX Topco Ltd | 110,028 | 0.28% | $114.43K | +6,933 | 0.00% |
| State Street Corp | 105,875 | 0.27% | $110.11K | −277,316 | 0.00% |
| Citadel Advisors LLC | 102,518 | 0.26% | $106.62K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 80 | 12M | 30.8% | 24 / 27 | 20 / 22 | 3M | 4M |
| Q1 2026 | 80 | 13M | 32.3% | 16 / 21 | 23 / 11 | 2M | 2M |
| Q4 2025 | 76 | 14M | 35.8% | 19 / 28 | 12 / 9 | 3M | 2M |
| Q3 2025 | 66 | 14M | 34.5% | 13 / 20 | 20 / 29 | 2M | 8M |
| Q2 2025 | 82 | 19M | 48.5% | 28 / 30 | 15 / 22 | 7M | 3M |
| Q1 2025 | 76 | 16M | 40.3% | 14 / 36 | 17 / 8 | 3M | 2M |
| Q4 2024 | 71 | 15M | 37.1% | 34 / 15 | 12 / 4 | 5M | 0M |
| Q3 2024 | 41 | 10M | 24.8% | 12 / 13 | 7 / 3 | 2M | 0M |
| Q2 2024 | 34 | 12M | 29.2% | 5 / 13 | 6 / 5 | 2M | 0M |
| Q1 2024 | 34 | 10M | 25.1% | 7 / 14 | 7 / 10 | 2M | 2M |
| Q4 2023 | 37 | 9M | 23.9% | 17 / 12 | 4 / 4 | 4M | 1M |
| Q3 2023 | 24 | 6M | 15.5% | 10 / 6 | 3 / 1 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MYO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,242,244 | 3.14% | $1.29M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 372,587 | 0.94% | $387.49K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 219,059 | 0.55% | $238.77K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 180,461 | 0.46% | $196.70K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 47,667 | 0.12% | $51.96K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 45,583 | 0.12% | $49.69K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 31,752 | 0.08% | $34.61K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 21,739 | 0.05% | $22.61K | 0.00% | Jun 30, 2026 |
| Small Cap Index Fund | 13,237 | 0.03% | $14.43K | 0.00% | May 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 10,229 | 0.03% | $10.64K | 0.00% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 6,508 | 0.02% | $6.77K | 0.00% | Jun 30, 2026 |
| ProShares Russell 2000 High Income ETF | 1,694 | 0.00% | $1.85K | 0.00% | May 31, 2026 |
| ProShares UltraPro Russell2000 | 1,334 | 0.00% | $1.45K | 0.00% | May 31, 2026 |
| ProShares Ultra Russell2000 | 1,324 | 0.00% | $1.44K | 0.00% | May 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 203 | 0.00% | $211 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul R. Gudonis | Chief Executive Officer, Director | 1,434,679 | 3.62% | Aug 11, 2026 |
| Harry Kovelman | Chief Medical Officer | 90,245 | 0.23% | Sep 14, 2026 |
| Micah Mitchell | Chief Commercial Officer | 152,297 | 0.38% | Aug 11, 2026 |
| David A. Henry | Chief Financial Officer | 470,163 | 1.19% | Aug 11, 2026 |
| Milton Mayo Morris | Director | 208,391 | 0.53% | Sep 4, 2026 |
| Heather C. Getz | Director | 210,458 | 0.53% | Jun 26, 2026 |
| Joseph M. Manko Jr. | Director | 2,388,479 | 6.03% | Jun 26, 2026 |
| William J. Febbo | Director | 123,704 | 0.31% | Jun 26, 2026 |
| Thomas F. Kirk | Director | 772,569 | 1.95% | Jun 26, 2026 |
| Thomas Aloysius Crowley Jr. | Director | 154,931 | 0.39% | Jun 26, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Harry Kovelman Chief Medical Officer | Sep 11, 2026 | Sale | −15,488 | $1.27 | $19.67K | 90,245 |
| Milton Mayo Morris Director | Sep 2, 2026 | Sale | −15,000 | $1.41 | $21.15K | 208,391 |
| Harry Kovelman Chief Medical Officer | Aug 20, 2026 | Sale | −17,500 | $1.73 | $30.28K | 105,733 |
| Harry Kovelman Chief Medical Officer | Aug 20, 2026 | Sale | −17,250 | $1.73 | $29.84K | 105,983 |
| Micah Mitchell Chief Commercial Officer | Aug 7, 2026 | Award | +58,409 | – | – | 152,297 |
| Micah Mitchell Chief Commercial Officer | Aug 7, 2026 | Tax withholding | −21,559 | $1.42 | $30.61K | 130,738 |
| David A. Henry Chief Financial Officer | Aug 7, 2026 | Tax withholding | −25,310 | $1.42 | $35.94K | 470,163 |
| David A. Henry Chief Financial Officer | Aug 7, 2026 | Award | +68,644 | – | – | 495,473 |
| Paul R. Gudonis Chief Executive Officer, Director | Aug 7, 2026 | Award | +146,909 | – | – | 1,434,679 |
| Harry Kovelman Chief Medical Officer | Aug 7, 2026 | Award | +55,149 | – | – | 145,690 |
| Harry Kovelman Chief Medical Officer | Aug 7, 2026 | Tax withholding | −22,457 | $1.42 | $31.89K | 123,233 |
| David A. Henry Chief Financial Officer | Jul 13, 2026 | Tax withholding | −5,166 | $1.09 | $5.63K | 426,829 |
| David A. Henry Chief Financial Officer | Jul 10, 2026 | Award | +7,840 | – | – | 431,995 |
| Paul R. Gudonis Chief Executive Officer, Director | Jul 10, 2026 | Award | +10,454 | – | – | 1,287,770 |
| Thomas F. Kirk Director | Jun 25, 2026 | Award | +78,704 | – | – | 772,569 |
| Milton Mayo Morris Director | Jun 25, 2026 | Award | +78,704 | – | – | 223,391 |
| William J. Febbo Director | Jun 25, 2026 | Award | +78,704 | – | – | 123,704 |
| Joseph M. Manko Jr. Director | Jun 25, 2026 | Award | +78,704 | – | – | 78,704 |
| Thomas Aloysius Crowley Jr. Director | Jun 25, 2026 | Award | +78,704 | – | – | 154,452 |
| Heather C. Getz Director | Jun 25, 2026 | Award | +78,704 | – | – | 210,458 |
| David A. Henry Chief Financial Officer | Jun 12, 2026 | Tax withholding | −10,969 | – | – | 424,155 |
| Micah Mitchell Chief Commercial Officer | Jun 12, 2026 | Tax withholding | −9,061 | $1.20 | $10.87K | 93,888 |
| Harry Kovelman Chief Medical Officer | Jun 12, 2026 | Tax withholding | −10,442 | $1.20 | $12.53K | 90,541 |
| Harry Kovelman Chief Medical Officer | Jun 8, 2026 | Tax withholding | −7,635 | $1.33 | $10.15K | 100,983 |
| David A. Henry Chief Financial Officer | Jun 8, 2026 | Tax withholding | −10,050 | – | – | 435,124 |
| Micah Mitchell Chief Commercial Officer | Jun 8, 2026 | Tax withholding | −6,529 | $1.33 | $8.68K | 102,949 |
| Thomas F. Kirk Director | Jun 5, 2026 | Buy | +40,002 | $1.27 | $50.80K | 693,865 |
| Thomas F. Kirk Director | May 28, 2026 | Buy | +25,000 | $0.99 | $24.75K | 653,863 |
| Harry Kovelman Chief Medical Officer | May 28, 2026 | Sale | −11,536 | $1.02 | $11.77K | 108,618 |
| Harry Kovelman Chief Medical Officer | May 27, 2026 | Sale | −20,464 | $1.00 | $20.46K | 120,154 |
| Thomas F. Kirk Director | May 18, 2026 | Buy | +43,401 | $0.91 | $39.49K | 628,863 |
| Joseph M. Manko Jr. Director | May 15, 2026 | Buy | +30,367 | $0.89 | $27.03K | 2,309,775 |
| Thomas F. Kirk Director | May 15, 2026 | Buy | +31,605 | $0.91 | $28.76K | 585,462 |
| Micah Mitchell Chief Commercial Officer | May 14, 2026 | Sale | −90,231 | $0.86 | $77.60K | 109,478 |
| Joseph M. Manko Jr. Director | May 14, 2026 | Buy | +170,830 | $0.86 | $146.91K | 2,279,408 |
| William J. Febbo Director | Apr 14, 2026 | Award | +45,000 | – | – | 45,000 |
| David A. Henry Chief Financial Officer | Apr 13, 2026 | Tax withholding | −3,953 | $0.71 | $2.81K | 445,174 |
| Paul R. Gudonis Chief Executive Officer, Director | Apr 10, 2026 | Award | +19,395 | – | – | 1,280,045 |
| Paul R. Gudonis Chief Executive Officer, Director | Apr 10, 2026 | Award | +16,666 | – | – | 1,277,316 |
| David A. Henry Chief Financial Officer | Apr 10, 2026 | Award | +12,500 | – | – | 449,127 |
| Heather C. Getz Director | Mar 16, 2026 | Buy | +20,000 | $0.70 | $14.00K | 131,754 |
| Thomas F. Kirk Director | Mar 13, 2026 | Buy | +72,000 | $0.71 | $51.12K | 553,857 |
| Heather C. Getz Director | Mar 12, 2026 | Buy | +70,000 | $0.73 | $51.10K | 111,754 |
| David A. Henry Chief Financial Officer | Jan 12, 2026 | Award | +8,727 | – | – | 436,627 |
| Paul R. Gudonis Chief Executive Officer, Director | Jan 12, 2026 | Award | +11,637 | – | – | 1,260,650 |
| Thomas F. Kirk Director | Nov 21, 2025 | Buy | +2,535 | $0.72 | $1.83K | 481,857 |
| Thomas F. Kirk Director | Nov 20, 2025 | Buy | +4,902 | $0.72 | $3.53K | 479,322 |
| Thomas Aloysius Crowley Jr. Director | Nov 19, 2025 | Buy | +385 | $0.77 | $296 | 479 |
| Thomas Aloysius Crowley Jr. Director | Nov 18, 2025 | Buy | +4,000 | $0.73 | $2.92K | 75,748 |
| Paul R. Gudonis Chief Executive Officer, Director | Sep 9, 2025 | Gift | −10,000 | – | – | 1,249,013 |
| Thomas F. Kirk Director | Aug 25, 2025 | Buy | +50,000 | $1.15 | $57.50K | 474,420 |
| Thomas F. Kirk Director | Aug 18, 2025 | Buy | +50,000 | $1.10 | $55.00K | 424,420 |
| Paul R. Gudonis Chief Executive Officer, Director | Aug 15, 2025 | Buy | +50,000 | $0.95 | $47.50K | 1,259,013 |
| Harry Kovelman Chief Medical Officer | Jun 30, 2025 | Tax withholding | −13,054 | $2.19 | $28.59K | 140,618 |
| David A. Henry Chief Financial Officer | Jun 30, 2025 | Tax withholding | −23,587 | $2.19 | $51.66K | 427,900 |
| Micah Mitchell Chief Commercial Officer | Jun 11, 2025 | Award | +59,440 | – | – | 199,709 |
| Harry Kovelman Chief Medical Officer | Jun 11, 2025 | Award | +62,938 | – | – | 153,672 |
| David A. Henry Chief Financial Officer | Jun 11, 2025 | Award | +76,398 | – | – | 451,487 |
| Paul R. Gudonis Chief Executive Officer, Director | Jun 11, 2025 | Award | +157,342 | – | – | 1,209,013 |
| Thomas F. Kirk Director | Jun 11, 2025 | Award | +29,720 | – | – | 374,420 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Henry David Officer | Oct 13, 2026 | 3,133 | $4.29K | Oct 12, 2026 | Vesting of Restricted Stock Units |
| Kovelman Harry Officer | Sep 11, 2026 | 15,844 | $20.14K | Sep 11, 2026 | Restricted Stock |
| Milton Mayo Morris Director | Sep 2, 2026 | 15,000 | $21.15K | Sep 2, 2026 | RSU VEST |
| Kovelman Harry Officer | Aug 20, 2026 | 17,500 | $30.33K | Aug 20, 2026 | Restricted Stock |
| Henry David Officer | Jul 13, 2026 | 5,166 | $5.63K | Jul 13, 2026 | Vesting of Restricted Stock Units |
| Mitchell Micah Officer | Jun 12, 2026 | 9,061 | $10.87K | Jun 12, 2026 | Vesting of Restricted Stock Units |
| Kovelman Harry Officer | Jun 12, 2026 | 10,442 | $12.53K | Jun 12, 2026 | Vesting of Restricted Stock Units |
| Mitchell Micah Officer | Jun 8, 2026 | 6,529 | $8.68K | Jun 8, 2026 | Vesting of Restricted Stock Units |
| Kovelman Harry Officer | Jun 8, 2026 | 7,635 | $10.15K | Jun 8, 2026 | Vesting of Restricted Stock Units |
| Kovelman Harry Officer | May 28, 2026 | 11,536 | $11.73K | May 28, 2026 | Restricted Stock |
| Kovelman Harry Officer | May 27, 2026 | 20,464 | $20.47K | May 27, 2026 | Restricted Stock |
| Mitchell Micah Officer | May 14, 2026 | 90,231 | $77.69K | May 14, 2026 | Restricted Stock |
| Henry David Officer | Apr 13, 2026 | 3,953 | $2.81K | Apr 13, 2026 | Vesting of Restricted Stock Units |
| Kovelman Harry Officer | Jun 30, 2025 | 13,054 | $28.59K | Jun 28, 2025 | Vesting of Restricted Stock Units |
| Henry David Officer | Jun 30, 2025 | 23,587 | $51.66K | Jun 30, 2025 | Vesting of Restricted Stock Units |